Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
REGENXBIO Inc. - Common Stock
(NQ:
RGNX
)
8.160
-0.340 (-4.00%)
Streaming Delayed Price
Updated: 11:46 AM EST, Feb 12, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
306,839
Open
8.490
Bid (Size)
8.130 (100)
Ask (Size)
8.170 (600)
Prev. Close
8.500
Today's Range
8.115 - 8.541
52wk Range
5.035 - 16.19
Shares Outstanding
43,466,186
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Biotech Beat Nvidia in 2025. Can It Do It Again?
↗
February 11, 2026
Big pharma and biotech take the earnings stage with reports from Eli Lilly and Novo Nordisk leading the lineup. Will they help the industry once again outperform AI champ Nvidia?
Via
The Motley Fool
Topics
Artificial Intelligence
Regenxbio Stock Still Has Over 300% Upside Despite FDA Pushback On Hunter Syndrome Drug: Clear Street
↗
February 09, 2026
Clear Street pointed to strength in RGX-202 data for Duchenne and early results from Sura-Vec in wet AMD.
Via
Stocktwits
Performance
YTD
-39.9%
-39.9%
1 Month
-45.9%
-45.9%
3 Month
-29.7%
-29.7%
6 Month
-8.6%
-8.6%
1 Year
+11.3%
+11.3%
More News
Read More
Why Did RGNX Shares Plummet 19% After-Hours Today?
↗
February 09, 2026
Via
Stocktwits
Monday's after hours session: top gainers and losers
↗
February 09, 2026
Via
Chartmill
RGNX Shares Pare Losses As Wall Street Dismisses Gene Therapy Clinical Hold Spurred Selloff As An Overreaction
↗
January 28, 2026
Via
Stocktwits
Earnings Scheduled For November 6, 2025
↗
November 06, 2025
Via
Benzinga
Analyst Expectations For Regenxbio's Future
↗
August 19, 2025
Via
Benzinga
RGNX Investors Have Opportunity to Join REGENXBIO Inc. Fraud Investigation with the Schall Law Firm
February 03, 2026
From
The Schall Law Firm
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of REGENXBIO Inc. - RGNX
February 03, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Kaplan Fox Alerts Investors of REGENXBIO Inc. (RGNX) to an Investigation of Possible Securities Law Violations
January 28, 2026
Via
NewMediaWire
Kaplan Fox Alerts Investors of REGENXBIO Inc. (RGNX) to an Investigation of Possible Securities Law Violations
January 28, 2026
Via
TheNewswire.com
Gapping stocks in Wednesday's session
↗
January 28, 2026
Via
Chartmill
RGNX Stock Is Falling Today — What Is The FDA Update On REGENXBIO's Gene Therapy?
↗
January 28, 2026
Via
Stocktwits
Top movers in Wednesday's pre-market session
↗
January 28, 2026
Via
Chartmill
My Top 4 Stocks to Buy in Early 2026
↗
January 22, 2026
Via
The Motley Fool
Topics
Artificial Intelligence
Economy
Capricor Therapeutics (NASDAQ: CAPR) Soars 535% to Eight-Year High on Landmark Duchenne Muscular Dystrophy Treatment Results
December 03, 2025
Via
MarketMinute
REGENXBIO (RGNX) Q3 2025 Earnings Call Transcript
↗
November 27, 2025
Via
The Motley Fool
Topics
Earnings
REGENXBIO INC (NASDAQ:RGNX) Tops Q3 2025 Estimates, Shares Rise on Strong Results and Pipeline Progress
↗
November 06, 2025
Via
Chartmill
The Analyst Verdict: Regenxbio In The Eyes Of 7 Experts
↗
October 07, 2025
Via
Benzinga
7 Analysts Assess Regenxbio: What You Need To Know
↗
October 07, 2025
Via
Benzinga
A Glimpse Into The Expert Outlook On Regenxbio Through 6 Analysts
↗
September 08, 2025
Via
Benzinga
Regenxbio Unveils 12-Month Data For Gene Therapy Soon After FDA Delays Review Date
↗
September 05, 2025
Via
Benzinga
FDA Extends Decision Date On Regenxbio's Gene Therapy Into Next Year
↗
August 19, 2025
Via
Benzinga
Navigating the Currents: Top Sectors Primed for Growth in Q3 2025
August 27, 2025
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Retirement
REGENXBIO INC (NASDAQ:RGNX) Reports Q2 2025 Earnings Miss, Stock Slides Amid Revenue and EPS Shortfalls
↗
August 07, 2025
Via
Chartmill
Topics
Earnings
Frequently Asked Questions
Is REGENXBIO Inc. - Common Stock publicly traded?
Yes, REGENXBIO Inc. - Common Stock is publicly traded.
What exchange does REGENXBIO Inc. - Common Stock trade on?
REGENXBIO Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for REGENXBIO Inc. - Common Stock?
The ticker symbol for REGENXBIO Inc. - Common Stock is RGNX on the Nasdaq Stock Market
What is the current price of REGENXBIO Inc. - Common Stock?
The current price of REGENXBIO Inc. - Common Stock is 8.160
When was REGENXBIO Inc. - Common Stock last traded?
The last trade of REGENXBIO Inc. - Common Stock was at 02/12/26 11:46 AM ET
What is the market capitalization of REGENXBIO Inc. - Common Stock?
The market capitalization of REGENXBIO Inc. - Common Stock is 354.68M
How many shares of REGENXBIO Inc. - Common Stock are outstanding?
REGENXBIO Inc. - Common Stock has 355M shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
